Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346995 | 0.88 | USP2 (0.56) | USP2SMN1; SMN2GPR119CYP11B2ACACB | |
| SCHEMBL20937613 | 0.84 | USP2 (0.53) | USP2SMN1; SMN2GPR119CYP11B2HPGD | |
| SCHEMBL933177 | 0.84 | USP2 (0.53) | USP2SMN1; SMN2GPR119CYP11B2HPGD | |
| SCHEMBL742156 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL1779347 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2GPR119CYP11B2HPGD | |
| SCHEMBL20937760 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2GPR119CYP11B2HPGD | |
| SCHEMBL653566 | 0.82 | USP2 (0.58) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL30842433 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2GPR119CYP11B2ACACB | |
| SCHEMBL23257682 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2GPR119CYP11B2HPGD | |
| SCHEMBL21341638 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2GPR119CYP11B2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | USP2 3871/4885SMN1; SMN2 2731/4885GPR119 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.